<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-11-30" updated="2019-12-02">
  <drugbank-id primary="true">DB09539</drugbank-id>
  <drugbank-id>DB09540</drugbank-id>
  <name>Omega-3-acid ethyl esters</name>
  <description>Omega-3-acid ethyl esters are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia[FDA Label][A176687]. Omega-3-acid ethyl esters are currently marketed in the US, EU, and many other regions under the brand name Lovaza[FDA Label][L5849].</description>
  <cas-number>308081-97-2</cas-number>
  <unii>D87YGH4Z0Q</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A18890</ref-id>
        <pubmed-id>26097787</pubmed-id>
        <citation>Braeckman RA, Stirtan WG, Soni PN: Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy Subjects. Clin Pharmacol Drug Dev. 2014 Mar;3(2):101-108. Epub 2013 Oct 22.</citation>
      </article>
      <article>
        <ref-id>A176687</ref-id>
        <pubmed-id/>
        <citation>Koski R: Omega-3-acid Ethyl Esters (Lovaza) For Severe Hypertriglyceridemia Pharmacy and Therapeutics. 2008 May;33(5):271-303.</citation>
      </article>
      <article>
        <ref-id>A176708</ref-id>
        <pubmed-id>24184945</pubmed-id>
        <citation>Davidson MH: Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid. Curr Opin Lipidol. 2013 Dec;24(6):467-74. doi: 10.1097/MOL.0000000000000019.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L5849</ref-id>
        <title>Omega-3-acid ethyl esters 90 (K85EE)</title>
        <url>https://products.basf.com/en/K85EE-Omega-3-acid-ethyl-esters.html</url>
      </link>
      <link>
        <ref-id>L5852</ref-id>
        <title>Australian Public Assessment Report for Omega-3-acid ethyl esters 90</title>
        <url>https://www.tga.gov.au/sites/default/files/auspar-omacor.pdf</url>
      </link>
      <link>
        <ref-id>L2401</ref-id>
        <title>FDA reports</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205060Orig1s000PharmR.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Omega-3-Acid Ethyl Esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG)[FDA Label][A176687].</indication>
  <pharmacodynamics>Omega-3-acid ethyl esters reduce triglyceride production, increase fatty acid metabolism, inhibit the release of fatty acids, increase triglyceride clearance, and decrease production of very low density lipoprotein cholesterol(VLDL-C)[A176687].</pharmacodynamics>
  <mechanism-of-action>Omega-3-acid ethyl esters reduce triglyceride production by the liver but this mechanism is not well understood[A176687]. Omega-3-acid ethyl esters inhibit acyl-CoA:1,2-diacylglycerol acyltransferase, reducing triglyceride synthesis and increasing paroxysmal beta-oxidation, which increases fatty aside metabolism[A176687]. Omega-3-acid ethyl esters also inhibit the release of fatty acids by competing for enzymes involved in the synthesis of triglycerides, increase triglyceride clearance by increasing the activity of lipoprotein lipase, and decrease production of VLDL-C[A176687].</mechanism-of-action>
  <toxicity>In rats, omega-3-acid ethyl esters are not mutagenic or clastogenic and do not lead to impairment of fertility[FDA Label].&#13;
&#13;
Safety in human pregnancy have not been performed, however an embryocidal effect was seen in rats force fed 7 times the maximum recommended human dose[FDA Label]. The risk and benefit of treatment during pregnancy should be weighed before deciding on treatment[FDA Label].&#13;
&#13;
Animal studies in lactating rats have shown excretion of omega-3-acid ethyl esters at concentrations 6 to 14 times higher than in the serum of the mother, however the effects of this excretion on a mother or child have not been established[FDA Label].&#13;
&#13;
Safety and effectiveness in pediatric patients has not been established[FDA Label].&#13;
&#13;
There appear to be no differences in the safety and efficacy in patients above or below 60 years of age based on limited data[FDA Label].</toxicity>
  <metabolism>Omega-3-acid ethyl esters are hydrolysed to free fatty acids in the intestinal lumen by pancreatic lipase[A176708]. Once in enterocytes, the free fatty acids are packaged in chylomicrons which are released from cells into the circulation[A176708]. Fatty acids then enter the liver where they can be incorporated into liver stores, incorporated into lipoprotein phospholipids, or oxidised for energy[L5852].</metabolism>
  <absorption>Omega-3-acid ethyl esters are rapidly hydrolysed to free fatty acids in the intestinal lumen which then become incorporated into phospholipids, cholesterol, and triglycerides so determination of bioavailability by serum concentration is not possible[L5852,A176708].</absorption>
  <half-life>79 hours ± 47 hours[A18890].</half-life>
  <protein-binding>Because omega-3-acid ethyl esters are rapidly hydrolysed and incorporated into other processes and structures, protein binding data is scarce[FDA Label][L5852]. However, most of EPA is bound to plasma protein[L2401].</protein-binding>
  <route-of-elimination>Includes oxidative catabolism to carbon dioxide and water</route-of-elimination>
  <volume-of-distribution>82 ± 56L[A18890]</volume-of-distribution>
  <clearance>757 mL/h ± 283mL/h[A18890].</clearance>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Omega-3 fatty acid ethyl esters</synonym>
    <synonym language="english" coder="usan">Omega-3-acid ethyl esters</synonym>
  </synonyms>
  <products>
    <product>
      <name>Concept DHA</name>
      <labeller>Us Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>52747-621</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Divista</name>
      <labeller>Us Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>52747-110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lovaza</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5816</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 g/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021654</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lovaza</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-795</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 g/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021654</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lovaza</name>
      <labeller>Atlantic Biologicals Corps.</labeller>
      <ndc-id/>
      <ndc-product-code>17856-0084</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021654</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lovaza</name>
      <labeller>Atlantic Biologicals Corps.</labeller>
      <ndc-id/>
      <ndc-product-code>17856-0783</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021654</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lovaza</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-21</started-marketing-on>
      <ended-marketing-on>2012-07-30</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021654</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lovaza</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-1134</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-21</started-marketing-on>
      <ended-marketing-on>2013-11-30</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021654</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lovaza</name>
      <labeller>GlaxoSmithKline LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0173-0783</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-10-21</started-marketing-on>
      <ended-marketing-on>2019-10-31</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021654</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lovaza</name>
      <labeller>GlaxoSmithKline LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0173-0884</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021654</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Luvira</name>
      <labeller>Sterling-Knight Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69336-351</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mi-Omega NF</name>
      <labeller>Mayne Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>68308-502</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on>2016-05-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Multinate DHA</name>
      <labeller>River's Edge Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68032-445</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-01</started-marketing-on>
      <ended-marketing-on>2012-11-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Multinate DHA</name>
      <labeller>River's Edge Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68032-446</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-01</started-marketing-on>
      <ended-marketing-on>2011-04-20</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Multinate DHA Extra</name>
      <labeller>River's Edge Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68032-447</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-01</started-marketing-on>
      <ended-marketing-on>2011-04-20</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Multinate DHA Extra</name>
      <labeller>River's Edge Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68032-448</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-01</started-marketing-on>
      <ended-marketing-on>2012-03-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omacor</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code>65726-424</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on>2010-01-01</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 g/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021654</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3 Rx Complete</name>
      <labeller>Tmig, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69176-190</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090973</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3 Well Pack</name>
      <labeller>Tmig, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69176-011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090973</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-Acid Ethyl Ester</name>
      <labeller>Bionpharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69452-175</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206455</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-acid Ethyl Esters</name>
      <labeller>International Brand Management, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>69837-170</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>1 g/1g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090973</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-Acid Ethyl Esters</name>
      <labeller>Atlantic Biologicals Corps.</labeller>
      <ndc-id/>
      <ndc-product-code>17856-0034</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204940</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-acid Ethyl Esters</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-0027</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on>2018-06-08</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091018</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-Acid Ethyl Esters</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>49884-019</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091018</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-Acid Ethyl Esters</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-6805</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091018</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-acid ethyl esters</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-7015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-30</started-marketing-on>
      <ended-marketing-on>2017-06-30</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090973</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-acid ethyl esters</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>0254-3010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203893</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-acid ethyl esters</name>
      <labeller>Prasco Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>66993-839</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-06</started-marketing-on>
      <ended-marketing-on>2019-05-31</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021654</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-acid ethyl esters</name>
      <labeller>Prasco Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>66993-726</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-31</started-marketing-on>
      <ended-marketing-on>2020-03-31</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021654</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-Acid Ethyl Esters</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3956</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091018</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-acid ethyl esters</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3742</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090973</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-acid ethyl esters</name>
      <labeller>Camber Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>31722-936</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207420</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-acid ethyl esters</name>
      <labeller>AvKARE, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-657</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090973</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-acid ethyl esters</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090973</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-Acid Ethyl Esters</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-034</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204940</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-acid ethyl esters</name>
      <labeller>Apotex Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>60505-3170</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090973</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-acid ethyl esters</name>
      <labeller>Apotex Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>60505-4462</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090973</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-Acid Ethyl Esters</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-660</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204940</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-acid Ethyl Esters</name>
      <labeller>Direct_Rx</labeller>
      <ndc-id/>
      <ndc-product-code>72189-024</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090973</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-Acid Ethyl Esters</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5401</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091028</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-Acid Ethyl Esters</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2319</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204940</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-acid ethyl esters</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1636</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090973</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-Acid Ethyl Esters</name>
      <labeller>QPharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code>42708-067</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091028</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-Acid Ethyl Esters</name>
      <labeller>ANI Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62559-410</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211355</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-acid Ethyl Esters</name>
      <labeller>Strides Pharma Science Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64380-761</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203893</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omega-3-Acid Ethyl Esters</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-912</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091018</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omtryg</name>
      <labeller>Trygg Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>61112-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>900 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA204977</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Renate</name>
      <labeller>River's Edge Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68032-373</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-02</started-marketing-on>
      <ended-marketing-on>2010-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Renate</name>
      <labeller>River's Edge Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68032-340</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-02</started-marketing-on>
      <ended-marketing-on>2010-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Renate</name>
      <labeller>River's Edge Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68032-372</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-02</started-marketing-on>
      <ended-marketing-on>2011-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Renate DHA</name>
      <labeller>River's Edge Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68032-339</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-01</started-marketing-on>
      <ended-marketing-on>2010-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sure Result O3D3 System</name>
      <labeller>International Brand Management, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>69837-700</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090973</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tandem DHA</name>
      <labeller>Us Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>52747-904</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Triklo</name>
      <labeller>Key Therapeutics, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70868-150</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-08</started-marketing-on>
      <ended-marketing-on>2018-10-31</ended-marketing-on>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>1 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204940</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Divista</name>
      <ingredients>Biotin + Chromium picolinate + Cyanocobalamin + Folic acid + Omega-3-acid ethyl esters + Pyridoxine</ingredients>
    </mixture>
    <mixture>
      <name>Renate</name>
      <ingredients>Ascorbic acid + Beta carotene + Calcium carbonate + Cholecalciferol + Cupric oxide + Cyanocobalamin + Doconexent + Folic acid + Iron + Magnesium oxide + Nicotinamide + Omega-3-acid ethyl esters + Pyridoxine + Riboflavin + Thiamine + Vitamin E + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Concept DHA</name>
      <ingredients>Ascorbic acid + Biotin + Cupric sulfate + Cyanocobalamin + Ferrous fumarate + Folic acid + Iron + Magnesium sulfate + Niacin + Omega-3-acid ethyl esters + Pantothenic acid + Pyridoxine + Riboflavin + Thiamine + Zinc sulfate, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Renate</name>
      <ingredients>Ascorbic acid + Beta carotene + Calcium carbonate + Cholecalciferol + Cupric oxide + Cyanocobalamin + Doconexent + Folic acid + Iron + Magnesium oxide + Nicotinamide + Omega-3-acid ethyl esters + Pyridoxine + Riboflavin + Thiamine + Vitamin E + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Renate</name>
      <ingredients>Ascorbic acid + Beta carotene + Calcium carbonate + Cholecalciferol + Cupric oxide + Cyanocobalamin + Doconexent + Folic acid + Iron + Magnesium oxide + Nicotinamide + Omega-3-acid ethyl esters + Pyridoxine + Riboflavin + Thiamine + Vitamin E + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Renate DHA</name>
      <ingredients>Ascorbic acid + Beta carotene + Calcium carbonate + Cholecalciferol + Cupric oxide + Cyanocobalamin + Doconexent + Folic acid + Iron + Magnesium oxide + Nicotinamide + Omega-3-acid ethyl esters + Pyridoxine + Riboflavin + Thiamine + Vitamin E + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Tandem DHA</name>
      <ingredients>Ascorbic acid + Ferrous fumarate + Folic acid + Iron + Omega-3-acid ethyl esters + Pyridoxine</ingredients>
    </mixture>
    <mixture>
      <name>Omacor</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Lovaza</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Lovaza</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Multinate DHA</name>
      <ingredients>Ascorbic acid + Beta carotene + Calcium carbonate + Cholecalciferol + Cupric oxide + Cyanocobalamin + Doconexent + Folic acid + Iron + Magnesium oxide + Nicotinamide + Omega-3-acid ethyl esters + Pyridoxine + Riboflavin + Thiamine + Vitamin E + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Multinate DHA</name>
      <ingredients>Ascorbic acid + Beta carotene + Calcium carbonate + Cholecalciferol + Cupric oxide + Cyanocobalamin + Doconexent + Folic acid + Iron + Magnesium oxide + Nicotinamide + Omega-3-acid ethyl esters + Pyridoxine + Riboflavin + Thiamine + Vitamin E + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Multinate DHA Extra</name>
      <ingredients>Ascorbic acid + Beta carotene + Calcium carbonate + Cholecalciferol + Cupric oxide + Cyanocobalamin + Doconexent + Folic acid + Iron + Magnesium oxide + Nicotinamide + Omega-3-acid ethyl esters + Pyridoxine + Riboflavin + Thiamine + Vitamin E + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Multinate DHA Extra</name>
      <ingredients>Ascorbic acid + Beta carotene + Calcium carbonate + Cholecalciferol + Cupric oxide + Cyanocobalamin + Doconexent + Folic acid + Iron + Magnesium oxide + Nicotinamide + Omega-3-acid ethyl esters + Pyridoxine + Riboflavin + Thiamine + Vitamin E + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3 Well Pack</name>
      <ingredients>Omega-3-acid ethyl esters + Vitamin D</ingredients>
    </mixture>
    <mixture>
      <name>Lovaza</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-acid Ethyl Esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omtryg</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Lovaza</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-Acid Ethyl Esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Sure Result O3D3 System</name>
      <ingredients>Omega-3-acid ethyl esters + Vitamin D</ingredients>
    </mixture>
    <mixture>
      <name>Lovaza</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-acid Ethyl Esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-Acid Ethyl Esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-Acid Ethyl Esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Triklo</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-acid ethyl esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Mi-Omega NF</name>
      <ingredients>beta-Sitosterol + Cyanocobalamin + Folic acid + Omega-3-acid ethyl esters + Pyridoxine</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-acid ethyl esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Lovaza</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-acid ethyl esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-acid ethyl esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-Acid Ethyl Esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-acid ethyl esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3 Rx Complete</name>
      <ingredients>Ascorbic acid + Biotin + Calcium + Chromium nicotinate + Copper + Cyanocobalamin + Folic acid + Lycopene + Magnesium + Magnesium oxide + Nicotinamide + Omega-3-acid ethyl esters + Pantothenic acid + Phylloquinone + Riboflavin + Selenium + Thiamine + Vitamin A + Vitamin D + Vitamin E + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-acid ethyl esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-acid ethyl esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-acid ethyl esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Lovaza</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Lovaza</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-Acid Ethyl Esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-acid ethyl esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-acid ethyl esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-Acid Ethyl Esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-acid Ethyl Esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-Acid Ethyl Esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-Acid Ethyl Esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-acid ethyl esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-Acid Ethyl Esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-Acid Ethyl Ester</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-Acid Ethyl Esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-acid Ethyl Esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Luvira</name>
      <ingredients>(12R)-12-hydroxyeicosapentaenoic acid + Doconexent + Omega-3-acid ethyl esters</ingredients>
    </mixture>
    <mixture>
      <name>Omega-3-Acid Ethyl Esters</name>
      <ingredients>Omega-3-acid ethyl esters</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Autacoids</category>
      <mesh-id>D012898</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Diet, Food, and Nutrition</category>
      <mesh-id>D000066888</mesh-id>
    </category>
    <category>
      <category>Dietary Fats</category>
      <mesh-id>D004041</mesh-id>
    </category>
    <category>
      <category>Dietary Fats, Unsaturated</category>
      <mesh-id>D004042</mesh-id>
    </category>
    <category>
      <category>Eicosanoids</category>
      <mesh-id>D015777</mesh-id>
    </category>
    <category>
      <category>Fats</category>
      <mesh-id>D005223</mesh-id>
    </category>
    <category>
      <category>Fatty Acids</category>
      <mesh-id>D005227</mesh-id>
    </category>
    <category>
      <category>Fatty Acids, Omega-3</category>
      <mesh-id>D015525</mesh-id>
    </category>
    <category>
      <category>Fatty Acids, Unsaturated</category>
      <mesh-id>D005231</mesh-id>
    </category>
    <category>
      <category>Fish Oils</category>
      <mesh-id>D005395</mesh-id>
    </category>
    <category>
      <category>Food</category>
      <mesh-id>D005502</mesh-id>
    </category>
    <category>
      <category>Food and Beverages</category>
      <mesh-id>D019602</mesh-id>
    </category>
    <category>
      <category>Inflammation Mediators</category>
      <mesh-id>D018836</mesh-id>
    </category>
    <category>
      <category>Lipids</category>
      <mesh-id>D008055</mesh-id>
    </category>
    <category>
      <category>Nootropic Agents</category>
      <mesh-id>D018697</mesh-id>
    </category>
    <category>
      <category>Oils</category>
      <mesh-id>D009821</mesh-id>
    </category>
    <category>
      <category>Pharmaceutical Preparations</category>
      <mesh-id>D004364</mesh-id>
    </category>
    <category>
      <category>Physiological Phenomena</category>
      <mesh-id>D010829</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Capsule, liquid filled</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule, liquid filled</form>
      <route>Oral</route>
      <strength>900 mg/1</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule, liquid filled</form>
      <route>Oral</route>
      <strength>1 g/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>1 g/1g</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>900 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB09539.pdf?1554392941</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB09539.pdf?1554398334</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>Omega-3-acid ethyl esters may increase the antiplatelet activities of Ibrutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Drotrecogin alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Streptokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Anagrelide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Argatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Fondaparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan polysulfate</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Pentosan polysulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Dipyridamole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Iloprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Epoprostenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ximelagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Desmoteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Defibrotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ancrod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Beraprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Fibrinolysin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Fibrinolysin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Prasugrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06294</drugbank-id>
      <name>Semuloparin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Semuloparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Idraparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Cangrelor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Astaxanthin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Apixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Otamixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06679</drugbank-id>
      <name>Amediplase</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Amediplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Tinzaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ferulic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with (R)-warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Triflusal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ticagrelor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08994</drugbank-id>
      <name>Ditazole</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ditazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Vorapaxar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Edoxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Potassium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Dextran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Bemiparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Parnaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Desirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11154</drugbank-id>
      <name>Zinc citrate</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Zinc citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11166</drugbank-id>
      <name>Antithrombin Alfa</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Antithrombin Alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Protein C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Antithrombin III human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11984</drugbank-id>
      <name>Letaxaban</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Letaxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Darexaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Betrixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12726</drugbank-id>
      <name>Monteplase</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Monteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Gabexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Protein S human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13199</drugbank-id>
      <name>Brinase</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Brinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13616</drugbank-id>
      <name>Melagatran</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Melagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13646</drugbank-id>
      <name>Saruplase</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Saruplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with (S)-Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Tocopherylquinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14598</drugbank-id>
      <name>Edetate calcium disodium anhydrous</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Edetate calcium disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14600</drugbank-id>
      <name>Edetate disodium anhydrous</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Edetate disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14726</drugbank-id>
      <name>Dabigatran</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Dabigatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00063</drugbank-id>
      <name>Eptifibatide</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Eptifibatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ticlopidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Clopidogrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Tirofiban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Pentoxifylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01138</drugbank-id>
      <name>Sulfinpyrazone</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Sulfinpyrazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Cilostazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01207</drugbank-id>
      <name>Ridogrel</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ridogrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Sevoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Resveratrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Nimesulide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Tesmilifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ibudilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05767</drugbank-id>
      <name>Andrographolide</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Andrographolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06081</drugbank-id>
      <name>Caplacizumab</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Caplacizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Tranilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08887</drugbank-id>
      <name>Icosapent ethyl</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Icosapent ethyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09283</drugbank-id>
      <name>Trapidil</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Trapidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Naftopidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12163</drugbank-id>
      <name>Sarpogrelate</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Sarpogrelate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12321</drugbank-id>
      <name>Ifetroban</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ifetroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Nitroaspirin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ketanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Indobufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12749</drugbank-id>
      <name>Butylphthalide</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Butylphthalide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12771</drugbank-id>
      <name>Hydroxytyrosol</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Hydroxytyrosol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13036</drugbank-id>
      <name>Ramatroban</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ramatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13327</drugbank-id>
      <name>Picotamide</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Picotamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13367</drugbank-id>
      <name>Cloricromen</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Cloricromen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13400</drugbank-id>
      <name>Linsidomine</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Linsidomine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13510</drugbank-id>
      <name>Buflomedil</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Buflomedil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13929</drugbank-id>
      <name>Relcovaptan</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Relcovaptan.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties/>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Not Soluble</value>
      <source>[MSDS]</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>&lt;20</value>
      <source>[MSDS]</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>&gt;400</value>
      <source>[MSDS]</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910460</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Omega-3_acid_ethyl_esters</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="2">
      <id>BE0005540</id>
      <name>Sterol regulatory element-binding protein 1</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A176708</ref-id>
            <pubmed-id>24184945</pubmed-id>
            <citation>Davidson MH: Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid. Curr Opin Lipidol. 2013 Dec;24(6):467-74. doi: 10.1097/MOL.0000000000000019.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P36956" source="Swiss-Prot">
        <name>Sterol regulatory element-binding protein 1</name>
        <general-function>Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding</general-function>
        <specific-function>Transcriptional activator required for lipid homeostasis. Regulates transcription of the LDL receptor gene as well as the fatty acid and to a lesser degree the cholesterol synthesis pathway (By similarity). Binds to the sterol regulatory element 1 (SRE-1) (5'-ATCACCCCAC-3'). Has dual sequence specificity binding to both an E-box motif (5'-ATCACGTGA-3') and to SRE-1 (5'-ATCACCCCAC-3').</specific-function>
        <gene-name>SREBF1</gene-name>
        <locus/>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>488-508
548-568</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>121673.6</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11289</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P36956</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SRBP1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>BHLHD1</synonym>
          <synonym>Class D basic helix-loop-helix protein 1</synonym>
          <synonym>SREBP-1</synonym>
          <synonym>SREBP1</synonym>
          <synonym>Sterol regulatory element-binding transcription factor 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009288|Sterol regulatory element-binding protein 1
MDEPPFSEAALEQALGEPCDLDAALLTDIEDMLQLINNQDSDFPGLFDPPYAGSGAGGTD
PASPDTSSPGSLSPPPATLSSSLEAFLSGPQAAPSPLSPPQPAPTPLKMYPSMPAFSPGP
GIKEESVPLSILQTPTPQPLPGALLPQSFPAPAPPQFSSTPVLGYPSPPGGFSTGSPPGN
TQQPLPGLPLASPPGVPPVSLHTQVQSVVPQQLLTVTAAPTAAPVTTTVTSQIQQVPVLL
QPHFIKADSLLLTAMKTDGATVKAAGLSPLVSGTTVQTGPLPTLVSGGTILATVPLVVDA
EKLPINRLAAGSKAPASAQSRGEKRTAHNAIEKRYRSSINDKIIELKDLVVGTEAKLNKS
AVLRKAIDYIRFLQHSNQKLKQENLSLRTAVHKSKSLKDLVSACGSGGNTDVLMEGVKTE
VEDTLTPPPSDAGSPFQSSPLSLGSRGSGSGGSGSDSEPDSPVFEDSKAKPEQRPSLHSR
GMLDRSRLALCTLVFLCLSCNPLASLLGARGLPSPSDTTSVYHSPGRNVLGTESRDGPGW
AQWLLPPVVWLLNGLLVLVSLVLLFVYGEPVTRPHSGPAVYFWRHRKQADLDLARGDFAQ
AAQQLWLALRALGRPLPTSHLDLACSLLWNLIRHLLQRLWVGRWLAGRAGGLQQDCALRV
DASASARDAALVYHKLHQLHTMGKHTGGHLTATNLALSALNLAECAGDAVSVATLAEIYV
AAALRVKTSLPRALHFLTRFFLSSARQACLAQSGSVPPAMQWLCHPVGHRFFVDGDWSVL
STPWESLYSLAGNPVDPLAQVTQLFREHLLERALNCVTQPNPSPGSADGDKEFSDALGYL
QLLNSCSDAAGAPAYSFSISSSMATTTGVDPVAKWWASLTAVVIHWLRRDEEAAERLCPL
VEHLPRVLQESERPLPRAALHSFKAARALLGCAKAESGPASLTICEKASGYLQDSLATTP
ASSSIDKAVQLFLCDLLLVVRTSLWRQQQPPAPAPAAQGTSSRPQASALELRGFQRDLSS
LRRLAQSFRPAMRRVFLHEATARLMAGASPTRTHQLLDRSLRRRAGPGGKGGAVAELEPR
PTRREHAEALLLASCYLPPGFLSAPGQRVGMLAEAARTLEKLGDRRLLHDCQQMLMRLGG
GTTVTSS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013721|Sterol regulatory element-binding protein 1 (SREBF1)
ATGGACGAGCCACCCTTCAGCGAGGCGGCTTTGGAGCAGGCGCTGGGCGAGCCGTGCGAT
CTGGACGCGGCGCTGCTGACCGACATCGAAGGTGAAGTCGGCGCGGGGAGGGGTAGGGCC
AACGGCCTGGACGCCCCAAGGGCGGGCGCAGATCGCGGAGCCATGGATTGCACTTTCGAA
GACATGCTTCAGCTTATCAACAACCAAGACAGTGACTTCCCTGGCCTATTTGACCCACCC
TATGCTGGGAGTGGGGCAGGGGGCACAGACCCTGCCAGCCCCGATACCAGCTCCCCAGGC
AGCTTGTCTCCACCTCCTGCCACATTGAGCTCCTCTCTTGAAGCCTTCCTGAGCGGGCCG
CAGGCAGCGCCCTCACCCCTGTCCCCTCCCCAGCCTGCACCCACTCCATTGAAGATGTAC
CCGTCCATGCCCGCTTTCTCCCCTGGGCCTGGTATCAAGGAAGAGTCAGTGCCACTGAGC
ATCCTGCAGACCCCCACCCCACAGCCCCTGCCAGGGGCCCTCCTGCCACAGAGCTTCCCA
GCCCCAGCCCCACCGCAGTTCAGCTCCACCCCTGTGTTAGGCTACCCCAGCCCTCCGGGA
GGCTTCTCTACAGGAAGCCCTCCCGGGAACACCCAGCAGCCGCTGCCTGGCCTGCCACTG
GCTTCCCCGCCAGGGGTCCCGCCCGTCTCCTTGCACACCCAGGTCCAGAGTGTGGTCCCC
CAGCAGCTACTGACAGTCACAGCTGCCCCCACGGCAGCCCCTGTAACGACCACTGTGACC
TCGCAGATCCAGCAGGTCCCGGTCCTGCTGCAGCCCCACTTCATCAAGGCAGACTCGCTG
CTTCTGACAGCCATGAAGACAGACGGAGCCACTGTGAAGGCGGCAGGTCTCAGTCCCCTG
GTCTCTGGCACCACTGTGCAGACAGGGCCTTTGCCGACCCTGGTGAGTGGCGGAACCATC
TTGGCAACAGTCCCACTGGTCGTAGATGCGGAGAAGCTGCCTATCAACCGGCTCGCAGCT
GGCAGCAAGGCCCCGGCCTCTGCCCAGAGCCGTGGAGAGAAGCGCACAGCCCACAACGCC
ATTGAGAAGCGCTACCGCTCCTCCATCAATGACAAAATCATTGAGCTCAAGGATCTGGTG
GTGGGCACTGAGGCAAAGCTGAATAAATCTGCTGTCTTGCGCAAGGCCATCGACTACATT
CGCTTTCTGCAACACAGCAACCAGAAACTCAAGCAGGAGAACCTAAGTCTGCGCACTGCT
GTCCACAAAAGCAAATCTCTGAAGGATCTGGTGTCGGCCTGTGGCAGTGGAGGGAACACA
GACGTGCTCATGGAGGGCGTGAAGACTGAGGTGGAGGACACACTGACCCCACCCCCCTCG
GATGCTGGCTCACCTTTCCAGAGCAGCCCCTTGTCCCTTGGCAGCAGGGGCAGTGGCAGC
GGTGGCAGTGGCAGTGACTCGGAGCCTGACAGCCCAGTCTTTGAGGACAGCAAGGCAAAG
CCAGAGCAGCGGCCGTCTCTGCACAGCCGGGGCATGCTGGACCGCTCCCGCCTGGCCCTG
TGCACGCTCGTCTTCCTCTGCCTGTCCTGCAACCCCTTGGCCTCCTTGCTGGGGGCCCGG
GGGCTTCCCAGCCCCTCAGATACCACCAGCGTCTACCATAGCCCTGGGCGCAACGTGCTG
GGCACCGAGAGCAGAGATGGCCCTGGCTGGGCCCAGTGGCTGCTGCCCCCAGTGGTCTGG
CTGCTCAATGGGCTGTTGGTGCTCGTCTCCTTGGTGCTTCTCTTTGTCTACGGTGAGCCA
GTCACACGGCCCCACTCAGGCCCCGCCGTGTACTTCTGGAGGCATCGCAAGCAGGCTGAC
CTGGACCTGGCCCGGGGAGACTTTGCCCAGGCTGCCCAGCAGCTGTGGCTGGCCCTGCGG
GCACTGGGCCGGCCCCTGCCCACCTCCCACCTGGACCTGGCTTGTAGCCTCCTCTGGAAC
CTCATCCGTCACCTGCTGCAGCGTCTCTGGGTGGGCCGCTGGCTGGCAGGCCGGGCAGGG
GGCCTGCAGCAGGACTGTGCTCTGCGAGTGGATGCTAGCGCCAGCGCCCGAGACGCAGCC
CTGGTCTACCATAAGCTGCACCAGCTGCACACCATGGGGAAGCACACAGGCGGGCACCTC
ACTGCCACCAACCTGGCGCTGAGTGCCCTGAACCTGGCAGAGTGTGCAGGGGATGCCGTG
TCTGTGGCGACGCTGGCCGAGATCTATGTGGCGGCTGCATTGAGAGTGAAGACCAGTCTC
CCACGGGCCTTGCATTTTCTGACACGCTTCTTCCTGAGCAGTGCCCGCCAGGCCTGCCTG
GCACAGAGTGGCTCAGTGCCTCCTGCCATGCAGTGGCTCTGCCACCCCGTGGGCCACCGT
TTCTTCGTGGATGGGGACTGGTCCGTGCTCAGTACCCCATGGGAGAGCCTGTACAGCTTG
GCCGGGAACCCAGTGGACCCCCTGGCCCAGGTGACTCAGCTATTCCGGGAACATCTCTTA
GAGCGAGCACTGAACTGTGTGACCCAGCCCAACCCCAGCCCTGGGTCAGCTGATGGGGAC
AAGGAATTCTCGGATGCCCTCGGGTACCTGCAGCTGCTGAACAGCTGTTCTGATGCTGCG
GGGGCTCCTGCCTACAGCTTCTCCATCAGTTCCAGCATGGCCACCACCACCGGCGTAGAC
CCGGTGGCCAAGTGGTGGGCCTCTCTGACAGCTGTGGTGATCCACTGGCTGCGGCGGGAT
GAGGAGGCGGCTGAGCGGCTGTGCCCGCTGGTGGAGCACCTGCCCCGGGTGCTGCAGGAG
TCTGAGAGACCCCTGCCCAGGGCAGCTCTGCACTCCTTCAAGGCTGCCCGGGCCCTGCTG
GGCTGTGCCAAGGCAGAGTCTGGTCCAGCCAGCCTGACCATCTGTGAGAAGGCCAGTGGG
TACCTGCAGGACAGCCTGGCTACCACACCAGCCAGCAGCTCCATTGACAAGGCCGTGCAG
CTGTTCCTGTGTGACCTGCTTCTTGTGGTGCGCACCAGCCTGTGGCGGCAGCAGCAGCCC
CCGGCCCCGGCCCCAGCAGCCCAGGGCACCAGCAGCAGGCCCCAGGCTTCCGCCCTTGAG
CTGCGTGGCTTCCAACGGGACCTGAGCAGCCTGAGGCGGCTGGCACAGAGCTTCCGGCCC
GCCATGCGGAGGGTGTTCCTACATGAGGCCACGGCCCGGCTGATGGCGGGGGCCAGCCCC
ACACGGACACACCAGCTCCTCGACCGCAGTCTGAGGCGGCGGGCAGGCCCCGGTGGCAAA
GGAGGCGCGGTGGCGGAGCTGGAGCCGCGGCCCACGCGGCGGGAGCACGCGGAGGCCTTG
CTGCTGGCCTCCTGCTACCTGCCCCCCGGCTTCCTGTCGGCGCCCGGGCAGCGCGTGGGC
ATGCTGGCTGAGGCGGCGCGCACACTCGAGAAGCTTGGCGATCGCCGGCTGCTGCACGAC
TGTCAGCAGATGCTCATGCGCCTGGGCGGTGGGACCACTGTCACTTCCAGCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00010</identifier>
            <name>HLH</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>ER to Golgi transport vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear envelope</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chromatin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II core promoter proximal region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sterol response element binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to fatty acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to starvation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholesterol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lung development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cholesterol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of histone deacetylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of triglyceride biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of fatty acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of heart rate by chemical signal</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of mitophagy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of protein stability</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of protein targeting to mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cAMP</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to food</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to glucagon</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to glucose</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to progesterone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to retinoic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="1">
      <id>BE0000105</id>
      <name>Sterol O-acyltransferase 1</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P35610" source="Swiss-Prot">
        <name>Sterol O-acyltransferase 1</name>
        <general-function>Sterol o-acyltransferase activity</general-function>
        <specific-function>Catalyzes the formation of fatty acid-cholesterol esters, which are less soluble in membranes than cholesterol. Plays a role in lipoprotein assembly and dietary cholesterol absorption. In addition to its acyltransferase activity, it may act as a ligase.</specific-function>
        <gene-name>SOAT1</gene-name>
        <locus>1q25</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>141-159
182-201
225-243
247-264
502-517</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.18</theoretical-pi>
        <molecular-weight>64733.975</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11177</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SOAT1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L21934</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4878022</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35610</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SOAT1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.3.1.26</synonym>
          <synonym>ACACT</synonym>
          <synonym>ACACT1</synonym>
          <synonym>ACAT</synonym>
          <synonym>ACAT-1</synonym>
          <synonym>ACAT1</synonym>
          <synonym>Acyl-coenzyme A:cholesterol acyltransferase 1</synonym>
          <synonym>Cholesterol acyltransferase 1</synonym>
          <synonym>SOAT</synonym>
          <synonym>STAT</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000210|Sterol O-acyltransferase 1
MVGEEKMSLRNRLSKSRENPEEDEDQRNPAKESLETPSNGRIDIKQLIAKKIKLTAEAEE
LKPFFMKEVGSHFDDFVTNLIEKSASLDNGGCALTTFSVLEGEKNNHRAKDLRAPPEQGK
IFIARRSLLDELLEVDHIRTIYHMFIALLILFILSTLVVDYIDEGRLVLEFSLLSYAFGK
FPTVVWTWWIMFLSTFSVPYFLFQHWATGYSKSSHPLIRSLFHGFLFMIFQIGVLGFGPT
YVVLAYTLPPASRFIIIFEQIRFVMKAHSFVRENVPRVLNSAKEKSSTVPIPTVNQYLYF
LFAPTLIYRDSYPRNPTVRWGYVAMKFAQVFGCFFYVYYIFERLCAPLFRNIKQEPFSAR
VLVLCVFNSILPGVLILFLTFFAFLHCWLNAFAEMLRFGDRMFYKDWWNSTSYSNYYRTW
NVVVHDWLYYYAYKDFLWFFSKRFKSAAMLAVFAVSAVVHEYALAVCLSFFYPVLFVLFM
FFGMAFNFIVNDSRKKPIWNVLMWTSLFLGNGVLLCFYSQEWYARQHCPLKNPTFLDYVR
PRSWTCRYVF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016016|Sterol O-acyltransferase 1 (SOAT1)
ATGGAATTGAAGCCATTTTTTATGAAGGAAGTTGGCAGTCACTTTGATGATTTTGTGACC
AATCTCATTGAAAAGTCAGCATCATTAGATAATGGTGGGTGCGCTCTCACAACCTTTTCT
GTTCTTGAAGGAGAGAAAAACAACCATAGAGCGAAGGATTTGAGAGCACCTCCAGAACAA
GGAAAGATTTTTATTGCAAGGCGCTCTCTCTTAGATGAACTGCTTGAAGTGGACCACATC
AGAACAATATATCACATGTTTATTGCCCTCCTCATTCTCTTTATCCTCAGCACACTTGTA
GTAGATTACATTGATGAAGGAAGGCTGGTGCTTGAGTTCAGCCTCCTGTCTTATGCTTTT
GGCAAATTTCCTACCGTTGTTTGGACCTGGTGGATCATGTTCCTGTCTACATTTTCAGTT
CCCTATTTTCTGTTTCAACATTGGGCCACTGGCTATAGCAAGAGTTCTCATCCGCTGATC
CGTTCTCTCTTCCATGGCTTTCTTTTCATGATCTTCCAGATTGGAGTTCTAGGTTTTGGA
CCAACATATGTTGTGTTAGCATATACACTGCCACCAGCTTCCCGGTTCATCATTATATTC
GAGCAGATTCGTTTTGTAATGAAGGCCCACTCATTTGTCAGAGAGAACGTGCCTCGGGTA
CTAAATTCAGCTAAGGAGAAATCAAGCACTGTTCCAATACCTACAGTCAACCAGTATTTG
TACTTCTTATTTGCTCCTACCCTTATCTACCGTGACAGCTATCCCAGGAATCCCACTGTA
AGATGGGGTTATGTCGCTATGAAGTTTGCACAGGTCTTTGGTTGCTTTTTCTATGTGTAC
TACATCTTTGAAAGGCTTTGTGCCCCCTTGTTTCGGAATATCAAACAGGAGCCCTTCAGC
GCTCGTGTTCTGGTCCTATGTGTATTTAACTCCATCTTGCCAGGTGTGCTGATTCTCTTC
CTTACTTTTTTTGCCTTTTTGCACTGCTGGCTCAATGCCTTTGCTGAGATGTTACGCTTT
GGTGACAGGATGTTCTATAAGGATTGGTGGAACTCCACGTCATACTCCAACTATTATAGA
ACCTGGAATGTGGTGGTCCATGACTGGCTATATTACTATGCTTACAAGGACTTTCTCTGG
TTTTTCTCCAAGAGATTCAAATCTGCTGCCATGTTAGCTGTCTTTGCTGTATCTGCTGTA
GTACACGAATATGCCTTGGCTGTTTGCTTGAGCTTTTTCTATCCCGTGCTCTTCGTGCTC
TTCATGTTCTTTGGAATGGCTTTCAACTTCATTGTCAATGATAGTCGGAAAAAGCCGATT
TGGAATGTTCTGATGTGGACTTCTCTTTTCTTGGGCAATGGAGTCTTACTCTGCTTTTAT
TCTCAAGAATGGTATGCACGTCAGCACTGTCCTCTGAAAAATCCCACATTTTTGGATTAT
GTCCGGCCACGTTCCTGGACTTGTCGTTACGTGTTTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03062</identifier>
            <name>MBOAT</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cholesterol binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cholesterol O-acyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>fatty-acyl-CoA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sterol O-acyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholesterol efflux</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholesterol esterification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholesterol homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholesterol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholesterol storage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>macrophage derived foam cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of amyloid precursor protein biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>very-low-density lipoprotein particle assembly</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>